Current Report · Items 2.02, 9.01 · 8-K

SIGA Technologies Inc.

SIGANASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Aug 6, 2026Accepted Aug 6, 2026, 4:06 PM EDTCIK 1010086Accession 0001140361-26-031672

Company context

SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.

Current securities

SIGANASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing. The full text of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Filed exhibits (1)

EX-99.1 (by filename) ef20079446_ex99-1.htm

EX-99.1 2 ef20079446_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026 $37 Million of TPOXX Sales Generated in the Second Quarter Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, August 6, 2026 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2026. “In the second quarter, we delivered approximately $37 million of TPOXX to three customers: $24 million of IV TPOXX to the U.S. strategic national stockpile and $13 million of oral TPOXX to two international customers,” stated Diem Nguyen, Chief Executive Officer. “With product deliveries across the U.S., Europe, and the Asia- Pacific region, spanning multiple formulations, SIGA continues to execute its long-term plan of selling TPOXX across a diverse range of regions and customers.” Summary Financial Results ($ in millions, except Three Months Six Months per share amounts) Ended June 30 Ended June 30 …

Open exhibit ↗